Across TCGA pan-cancer cohorts, ELOCP14 RNA is linked to patient survival in 4 of 34 cancer types, making it the most broadly survival-associated ELOCP14 data layer.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher ELOCP14 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ELOCP14 expression acts as an unfavorable survival marker.
ESCA, STAD, and LAML are the cancer types where ELOCP14 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.